[A 30-year review of gastric cancer surgery: China has achieved leapfrog leadership].

Abstract

Gastric cancer is one of the most common malignant tumors in China. Over the past 30 years, remarkable progress has been made in the diagnosis and treatment of gastric cancer in China. Especially in the era of minimally invasive surgery, perioperative treatment, and immunotherapy, clinical studies initiated by China rank first in the world in both quantity and quality. The mortality rate of gastric cancer surgery is lower than 1%,ranking among the global leaders. Clinical research related to laparoscopy/robotics ranks among the top globally. The first prospective, multicenter, randomized controlled phase 3 trial on conversion therapy for stage IV gastric cancer with peritoneal metastasis has been completed. First-line immunotherapy/double immunotherapy for advanced gastric cancer and perioperative immunotherapy clinical trial are international leading. The second edition of the Guidelines for Integrated Diagnosis and Treatment of Gastric Cancer by Chinese Anti-Cancer Association uses evidence predominantly from China. The era of China leading international diagnosis and treatment of gastric cancer had arrived.